⌕
Pacific Biosciences of California · PACB · Nasdaq
Tenet 40 · Weak
Compare
$1.96−0.51%At closeTenet 40 · Weak
$1.96−0.01 (−0.51%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Pacific Biosciences of California (PACB) Stock

Pacific Biosciences of California (PACB) closed at $1.96 on Nov 13, 2026; its Tenet Score is 40 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$1.96
Nov 13, 2026
Market cap
$613.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
1.07 – 3.44
low → high
Tenet Score
40/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. scores 40/100. Weak. Quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 40 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
40/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
19
Health
61
Growth
40

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityFHealthCGrowthDMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
3.8×
price to fiscal 2025 sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−346.2%
fiscal 2025, before interest and tax
Net margin
−81.3%
TTM through Sep 30, 2026
Current ratio
4.62
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable p…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 48 US ETFs · top wrappers by weightSee all ETFs holding PACB →

What sector and industry is Pacific Biosciences of California in?

Pacific Biosciences of California is in the Healthcare sector and the Drugs industry.

What is Pacific Biosciences of California's Tenet Score?

Pacific Biosciences of California's Tenet Score is 40 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.